| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues: | ||||||||||
Products, net | ||||||||||
380,833 | 301,034 | 154,584 | 5,421 | - | - | - | - | - | - | - |
Revenue from research contracts and other grants | ||||||||||
- | - | - | - | 1,253 | 9,757 | 14,219 | 37,329 | 46,990 | 29,420 | 17,585 |
Total revenues | ||||||||||
380,833 | 301,034 | 154,584 | 5,421 | 1,253 | 9,757 | - | - | - | - | - |
Cost and expenses: | ||||||||||
Cost of sales (excluding amortization of in-licensed rights) | ||||||||||
56,586 | 34,193 | 7,353 | 101 | - | - | - | - | - | - | - |
Research and development | ||||||||||
560,909 | 401,843 | 166,707 | 188,272 | 146,394 | 94,231 | 72,909 | 52,402 | 66,862 | 35,972 | 24,396 |
Operating expenses: | ||||||||||
Selling, general and administrative | ||||||||||
284,812 | 207,761 | 122,682 | 83,749 | 75,043 | 49,315 | 31,594 | 14,630 | 16,055 | 14,382 | 8,696 |
Acquired in-process research and development | ||||||||||
173,240 | - | - | - | - | - | - | - | 0 | 0 | - |
Settlement and license charges | ||||||||||
10,000 | - | 28,427 | - | - | - | - | - | - | - | - |
Amortization of in-licensed rights | ||||||||||
800 | 900 | 1,053 | 29 | - | - | - | - | - | - | - |
Total cost and expenses | ||||||||||
1,086,396 | 644,662 | 326,222 | 272,151 | 221,437 | 143,546 | 104,503 | 67,032 | - | - | - |
Operating loss | ||||||||||
-705,563 | -343,628 | -171,638 | -266,730 | -220,184 | -133,789 | -90,284 | -29,703 | -35,927 | -20,934 | -15,507 |
Other income (loss): | ||||||||||
Loss on change in warrant valuation | ||||||||||
- | - | - | - | - | 2,779 | 22,027 | 91,938 | 33,022 | -11,502 | -9,198 |
Gain from sale of Priority Review Voucher | ||||||||||
- | - | 125,000 | - | - | - | - | - | - | - | - |
Other expense, net | ||||||||||
8,317 | 18,982 | 1,990 | -535 | 154 | 779 | 326 | 354 | 587 | 259 | -454 |
Total other income (loss) | ||||||||||
-8,317 | -18,982 | 123,010 | -535 | 154 | -2,000 | -21,701 | -91,584 | 33,609 | -11,243 | -9,652 |
Loss before income tax expense | ||||||||||
-713,880 | -362,610 | -48,628 | -267,265 | -220,030 | - | - | - | - | - | - |
Income tax expense | ||||||||||
1,195 | -692 | 2,060 | - | - | - | - | - | - | - | - |
Net loss | ||||||||||
-715,075 | -361,918 | -50,688 | -267,265 | -220,030 | -135,789 | -111,985 | -121,287 | -2,318 | -32,177 | -25,159 |
Write-down of short-term securities - available-for-sale | ||||||||||
- | - | - | - | - | - | - | - | 0 | 0 | - |
Realized gain on sale of available-for-sale securities | ||||||||||
- | - | - | - | - | - | - | - | 0 | 0 | - |
Unrealized gains on investments, net of tax | ||||||||||
149 | 280 | -259 | -9 | -16 | -95 | - | - | 0 | 0 | - |
Total other comprehensive income | ||||||||||
149 | 280 | -259 | -9 | -16 | -95 | - | - | 0 | 0 | - |
Comprehensive loss | ||||||||||
-714,926 | -361,638 | -50,947 | -267,274 | -220,046 | -135,884 | -111,985 | -121,287 | -2,318 | -32,177 | - |
Net (loss) income per share | ||||||||||
Basic (loss) earnings per share | ||||||||||
- | - | - | - | - | - | - | - | - | - | -0.27 |
Diluted (loss) earnings per share | ||||||||||
- | - | - | - | - | - | - | - | - | - | -0.27 |
Weighted average number of shares of common stock used in computing: | ||||||||||
Basic (loss) earnings per share | ||||||||||
- | - | - | - | - | - | - | - | - | - | 93,090 |
Diluted (loss) earnings per share | ||||||||||
- | - | - | - | - | - | - | - | - | - | 93,090 |
Net loss per share - basic and diluted | ||||||||||
-9.71 | -5.46 | -0.86 | -5.49 | -5.20 | -3.39 | -3.31 | -5.14 | -0.11 | -1.74 | - |
Weighted average number of shares of common stock used in computing basic and diluted net loss per share | ||||||||||
73,615 | 66,250 | 58,818 | 48,697 | 42,290 | 40,026 | 33,850 | 23,602 | 21,599 | 18,539 | - |